Griffith Health Institute is
recruiting participants for some
new research into Alzheimer’s
Disease (AD).
The trials will involve etanercept
(Enbrel), a drug used to treat
inflammatory conditions, and
researchers are seeking participants
aged 78 or older with late onset AD.
The study will run for a three
month period, with participants
receiving between eight and 12
injections of the drug, which has
a well-characterised safety profile
for its use to treat diseases such as
rheumatoid arthritis, the uni said.
US studies had shown an injection
in the base of the neck provided
“marked and rapid” improvements
in mental alertness and responses
of dementia patients, it said.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.